Effect and Mechanism of Transthyretin Over-Expression on Pro-liferation and Cell Cycle of Lung Cancer A549 Cells
-
Deqing Zhu
,
Xuan Li
,
Hao Gong
,
Jing Li
,
Xike Lu
,
Honggang Xia
,
Xia Chen
,
Lan Ma
,
Zhongyi Sun
,
Xun Zhang
,
Dongbin Wang
Abstract
Background: The effects of transthyretin (TTR) over-expression on the proliferation and cell cycle of non-small cell lung cancer (NSCLC) A549 cells and its possible mechanism were verified.
Methods: A total of 196 LC patients and 20 healthy controls were enrolled at Tianjin Hospital, Tianjin, China between Apr 2017 and Oct 2017. The serum TTR content was detected by ELISA. Through lentiviral transfection method, NSCLC cells were divided into non-transfected group (group A), negative control group (group B) transfected with empty vector and experimental group (group C) transfected with TTR over-expression. Cell proliferation was detected by CCK-8 method, TTR mRNA expression was detected by real-time quantitative polymerase chain reaction (RT-qPCR), and TTR protein expression was tested by Western blot (WB). Cell cycle was detected by flow cytometry, Wnt3a/β-catenin protein expression was detected by WB, and mRNA expression was detected by RT-qPCR.
Results: The serum TTR content in early, middle and late LC group was remarkably lower than that in healthy group (P<0.05). Compared with late stage, TTR content in early and middle stages of LC group was higher, and the difference was statistically marked (P < 0.05). The absorbance value of group C was lower than that of groups A and B, indicating that the cell proliferation activity dramatically decreased, with statistically marked difference (P<0.05). LC A549 cells in group C were obviously blocked in G2M, with statistical significance (P<0.05).
Conclusion: TTR over-expression can inhibit the proliferation of NSCLC A549 cells, and the expression is related to Wnt3a/β-catenin pathway. TTR in serum of patients was helpful for diagnosing LC and has certain clinical value.
2. Feng RM, Zong YN, Cao SM, et al (2019). Current cancer situation in China: good or bad news from the 2018 Global Can-cer Statistics. Cancer Commun (Lond), 39: 22.
3. Khorfan R, Kruser TJ, Coughlin JM, et al (2020). Survival of Primary Stereotactic Body Radiation Therapy Compared With Surgery for Operable Stage I/II Non-small Cell Lung Cancer. Ann Thorac Surg, 110(1): 228-234.
4. Casiraghi M, Bertolaccini L, Sedda G, et al (2020). Lung cancer surgery in oligometa-static patients: outcome and survival. Eur J Cardiothorac Surg, 57(6): 1173-1180.
5. Chi A, Fang W, Sun Y, et al (2019). Com-parison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy. JAMA Netw Open, 2(11): e1915724.
6. Uprety D, Arjyal L, Vallatharasu Y, et al (2020). Utilization of Surgery and Its Im-pact on Survival in Patients With Early Stage Small-cell Lung Cancer in the Unit-ed States. Clin Lung Cancer, 21(2): 186-193.e2.
7. Mei J, Guo C, Xia L, et al (2019). Long-term survival outcomes of video-assisted tho-racic surgery lobectomy for stage I-II non-small cell lung cancer are more fa-vorable than thoracotomy: a propensity score-matched analysis from a high-volume center in China. Transl Lung Can-cer Res, 8(2): 155-166.
8. Mulvihill MS, Cox ML, Becerra DC, et al (2018). Higher Use of Surgery Confers Superior Survival in Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg, 106(5): 1533-1540.
9. Shimura T, Shibata M, Gonda K, et al (2018). Serum transthyretin level is associ-ated with prognosis of patients with gas-tric cancer. J Surg Res, 227: 145-150.
10. Hao S, Sun S, Xiao X, et al (2016). Selective expression of transthyretin in subtypes of lung cancer. J Mol Histol, 47(3): 239-47.
11. Shimura T, Shibata M, Kofunato Y, et al (2018). Clinical significance of serum transthyretin level in patients with hepa-tocellular carcinoma. ANZ J Surg, 88(12): 1328-1332.
12. Chen J, Chen LJ, Xia YL, et al (2013). Iden-tification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol, 139(7): 1117-27.
13. Liu L, Sun S, Liu J, et al (2009). [A new se-rum biomarker for lung cancer - trans-thyretin]. Zhongguo Fei Ai Za Zhi, 12(4): 300-5.
14. Wang DB, Lu XK, Zhang X, et al (2016). Carbonic anhydrase 1 is a promising bi-omarker for early detection of non-small cell lung cancer. Tumour Biol, 37(1): 553-9.
15. Shi Q, Zhou Z, Ye N, et al (2017). MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Cancer Biomark, 20(4): 539-546.
16. Wang Y, Xu L, Jiang L (2015). miR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5. Biochem Biophys Res Commun, 458(3): 714-719.
17. Hou Z, Zhao W, Zhou J, et al (2014). A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol, 53: 380-388.
18. Schweigert FJ, Sehouli J (2005). Transthyret-in, a biomarker for nutritional status and ovarian cancer. Cancer Res, 65(3):1114.
19. Gericke B, Raila J, Sehouli J, et al (2005). Mi-croheterogeneity of transthyretin in se-rum and ascitic fluid of ovarian cancer patients. BMC Cancer, 5: 133.
20. Escher N, Kob R, Kaatz M, et al (2011). Confirmation of the biological signifi-cance of transthyretin as a biomarker for cutaneous T-cell lymphoma by its protein interaction partners. Mol Med Rep, 4(1): 157-61.
21. P Katare D, Malik S, J Mani R, et al (2018). Novel mutations in transthyretin gene as-sociated with hepatocellular carcinoma. Mol Carcinog, 57(1): 70-77.
22. Power DM, Elias NP, Richardson SJ, et al (2000). Evolution of the thyroid hor-mone-binding protein, transthyretin. Gen Comp Endocrinol, 119(3): 241-55.
23. Liotta LA, Petricoin EF (2006). Serum pep-tidome for cancer detection: spinning bi-ologic trash into diagnostic gold. J Clin Invest, 116(1): 26-30.
24. Lin S, Zhen Y, Guan Y, et al (2020). Roles of Wnt/β-Catenin Signaling Pathway Regulatory Long Non-Coding RNAs in the Pathogenesis of Non-Small Cell Lung Cancer. Cancer Manag Res, 12: 4181-4191.
25. Ai P, Xu X, Xu S, et al (2020). Overexpres-sion of Wnt7a enhances radiosensitivity of non-small-cell lung cancer via the Wnt/JNK pathway. Biol Open, 9(6): bio050575.
26. Sarode P, Zheng X, Giotopoulou GA, et al (2020). Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. Sci Adv, 6(23): eaaz6105.
27. Xie M, Cai L, Li J, et al (2020). FAM110B Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Inactivating Wnt/β-Catenin Signaling. On-co Targets Ther, 13: 4373-4384.
28. Song J, Wei QY (2020). GBP1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci, 24(10): 5465-5472.
29. Wang HX, Wang XY, Fei JW, et al (2020). microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/Β-catenin signal-ing pathway. J Biol Regul Homeost Agents, 34(3):825-835.
30. Xue S, Wu W, Wang Z, et al (2020). USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition via Wnt/β-Catenin Pathway. Front Pharmacol, 11: 668.
31. Liu L, Zhu H, Liao Y, et al (2020). Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4+/Nanog+ NSCLC cells. Biomed Pharmacother, 127: 110225.
32. Wei H, Zhang F, Wang J, et al (2020). De-hydroeffusol inhibits hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer cells through the in-activation of Wnt/β-catenin pathway. Bi-osci Rep, 40(5): BSR20194284.
| Files | ||
| Issue | Vol 50 No 4 (2021) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v50i4.5995 | |
| Keywords | ||
| Non-small cell lung cancer; Transthyretin Cell proliferation Cell cycle Serum marker | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
